Description: Ligand discovers, develops and markets new drugs for critical unmet medical needs in the areas of cancer, pain, skin diseases, hormone-related diseases, osteoporosis, metabolic disorders, cardiovascular and inflammatory diseases. Ligand's proprietary drug discovery and development programs are based on its leadership position in gene transcription technology related to intracellular receptors.
Exchange: PINK
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: |